Promising Results from Spinogenix's Phase 2 Trial of Tazbentetol for Schizophrenia Show Safety and Efficacy Spinogenix's Phase 2 trial data reveals early improvements in treating schizophrenia with Tazbentetol, highlighting safety and symptom reduction.

Promising Results from Spinogenix's Phase 2 Trial of Tazbentetol for Schizophrenia Show Safety and Efficacy #United_States #Los_Angeles #schizophrenia #Spinogenix #Tazbentetol

Spinogenix Concludes Patient Enrollment for Groundbreaking Schizophrenia Treatment Trial Spinogenix has successfully concluded patient enrollment for its Phase 2 trial of Tazbentetol, a novel treatment for schizophrenia, aiming to improve cognitive and negative symptoms.

Spinogenix Concludes Patient Enrollment for Groundbreaking Schizophrenia Treatment Trial #None #schizophrenia #Spinogenix #Tazbentetol

Spinogenix's Tazbentetol Shows Promise as Cognitive Therapy for Alzheimer's Disease Spinogenix's Phase 2a trial reveals Tazbentetol's potential in improving cognitive function in Alzheimer's patients, showing notable safety and efficacy.

Spinogenix's Tazbentetol Shows Promise as Cognitive Therapy for Alzheimer's Disease #USA #Los_Angeles #Alzheimer's #Spinogenix #Tazbentetol

Spinogenix Achieves WHO Approval for Tazbentetol, a Groundbreaking Alzheimer's Therapy Spinogenix, Inc. has announced that the WHO approved 'tazbentetol' as the non-proprietary name for its innovative therapy aimed at neurodegenerative conditions.

Spinogenix Achieves WHO Approval for Tazbentetol, a Groundbreaking Alzheimer's Therapy #USA #Los_Angeles #Alzheimer's #Spinogenix #Tazbentetol